Cancer, Hepatitis Drug Approvals Highlight SPT Week in Review

Article

Top news of the week from Specialty Pharmacy Times.

5. Direct-Acting Antivirals Slash the Risk of HCV-Associated Liver Cancer

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus. Read more.

4. FDA Approves First Treatment for Rare Blood Cancer

Vemurafenib (Zelboraf) receives priority review for Erdheim-Chester Disease. Read more.

3. Alectinib Approved as First-Line Lung Cancer Therapy

Alectinib (Alecensa) found to reduce the risk of disease progression in patients with metastatic non-small cell lung cancer. Read more.

2. FDA Approves Adcentris for Anaplastic Large Cell Lymphoma

Brentuximab vedotin (Adcentris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides. Read more.

1. FDA Approves New Hepatitis Therapy

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States. Read more.

Related Videos
Team of care workers with women at the center -- Image credit: Delmaine Donson/peopleimages.com | stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.